Luciferase News and Research

RSS

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

Researchers from Germany, in their recent study published in the journal Cellular & Molecular Immunology, have evaluated the mutations in the S protein of one such SARS-CoV-2 strain, a Delta sublineage AY.4.2, which is currently expanding in the UK, and have found that it neither contains any potential for increased cell entry nor antibody escape.

10 Jan 2022

Small molecule identified as a SARS-CoV-2 inhibitor

A new study published in iScience reports the results of a screening strategy to identify small molecules that target viral entry to block infection with this virus.

6 Jan 2022

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

In a new study, researchers determined CD8+ and CD4+ T cell responses against the SARS-CoV-2 Omicron variant in 51 individuals vaccinated with the messenger ribonucleic acid (mRNA)-based Pfizer and adenovirus vector-based Johnson & Johnson vaccines.

5 Jan 2022

mRNA booster vaccine confers strong protection against SARS-CoV-2 Omicron in cancer patients

A new preprint research paper posted to the medRxiv* server reports the induction of high neutralizing activity in these patients against the Omicron VOC with a booster dose.

5 Jan 2022

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

New findings indicate that TriSb92 is a potent inhibitor of SARS-CoV-2 infection targeting a conserved site in the RBD of the spike, which is insensitive for immune escape mutations found in the relevant variants of concern, including Omicron

31 Dec 2021

Nanoengineers develop a new approach to effectively deliver mRNA into cells

Nanoengineers at the University of California San Diego have developed a new and potentially more effective way to deliver messenger RNA (mRNA) into cells.

30 Nov 2021

Monitoring cellular metabolism for NAFLD/NASH liver disease research

In this interview, Jolanta Vidugiriene, a Senior Research Scientist at Promega Corporation, talks to News-Medical about tools for studying metabolism in NAFLD/NASH research.

From Promega Corporation 22 Nov 2021

P681H mutation helps SARS-CoV-2 VOCs replicate faster and resist innate immunity

In the current study, researchers compare the IFITM sensitivities of major SARS-CoV-2 VOCs.

17 Nov 2021

Discovery of new receptor that interacts with SARS-CoV-2 spike, suppresses infection

Researchers recently conducted a study to identify host factors affecting cellular interactions of the SARS-CoV-2 spike protein.

16 Nov 2021

Rare disease diagnosis by 100,000 genomes pilot

A team of researchers conducted a pilot study that enrolled families and undertook detailed clinical phenotyping of the proband to evaluate the effect of the whole genome sequencing approach on a genetic diagnosis of rare conditions by the NHS in the UK.

12 Nov 2021

The autoantibody profile in COVID-19 patients with MIS-C

A new study assessed the presence of autoantibodies against autoantigens associated with known autoimmune diseases in patients with COVID-19.

10 Nov 2021

Convalescent plasma post-vaccination increases binding and neutralizing antibodies against SARS-CoV-2 variants

A recent study assesses the boost in antibodies against SARS-CoV-2)variants post-vaccination in plasma samples from previously infected COVID-19 patients.

7 Nov 2021

SARS-CoV-2 variants neutralized by camel nanobodies

Researchers from the US recently isolated two VHH nanobodies - 7A3 and 8A2 - from dromedary camels (Camelus dromedaries) using phage display. These nanobodies were found to have a high affinity for the spike RBD and broad neutralization abilities against SARS-CoV-2 and its variants.

2 Nov 2021

Emerging SARS-CoV-2 variant A.30 efficiently evades vaccine-induced immunity

A recent study published in the journal Cellular & Molecular Immunology shows that a new A.30 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can evade vaccine-induced antibodies and might spread outside the lungs extraordinarily well, with important implications for our public health response.

1 Nov 2021

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.

25 Oct 2021

Potent extended anti- SARS-CoV-2 effect of titanium dioxide surface coatings

A team of researchers has explored the possibility of coating surfaces with TiO2 as a tool to inactivate SARS-CoV-2.

7 Oct 2021

non-RBD mutation in SARS-CoV-2 variants enhances resistance to neutralizing antibodies

Researchers from Ohio State University have been investigating mutations in the rest of the spike protein, particularly the Q677H mutation.

7 Oct 2021

SARS-CoV-2 infection aided by antibody-dependent enhancement

The coronavirus disease 2019 (COVID-19) pandemic has raised concerns about the detrimental effects of antibodies. Antibody-dependent enhancement (ADE) of infection is one of the biggest concerns in terms of not only the antibody reaction to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon reinfection with the virus but also the reaction to COVID-19 vaccines.

30 Sep 2021

A novel FACS-based approach for SARS-CoV-2 serology

A recent study discusses a simple, sensitive, and quantitative serological test based on FACS assay to evaluate antibodies against SARS-CoV-2.

20 Sep 2021

New vaccine platform can better induce anti-malaria immunity in the liver

Malaria remains a deadly disease that affects people worldwide, particularly in Africa. Caused by a parasite that can enter the human bloodstream via mosquito bite, the parasites can then infect and reproduce within the person's liver.

16 Sep 2021